Under construction – not a live service
Sign in

NCT05893537TerminatedPhase 2

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Source: ClinicalTrials.gov · Last updated 16 Apr 2025

Reason given: The trial was closed as part of a strategic business decision.

Brief summary (registry, in English)

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Status (registry)
Terminated
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
100 (actual)
First submitted
17 May 2023
Start date
16 Jun 2023
Primary completion date
4 Mar 2025
Lead sponsor
Cognition Therapeutics
NCT number
NCT05893537

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Intraocular surgery (including intraocular lens implantation surgery) within 3 months prior to randomization.

Other illness

  • Retinal disease other than dry AMD.
  • Any ophthalmologic condition that prevents adequate imaging of the retina as judged by the study site or central reading center.
  • Any ophthalmic condition that will or is likely to require surgery during the study period.
  • Hypersensitivity to fluorescein.
  • Suspected or known allergy to any components of the study treatments.
  • History of vitrectomy surgery, submacular surgery or any other surgical intervention for dry AMD.
  • History of glaucoma filtering surgery or corneal transplant in the study eye.
  • History of central serous retinopathy in either eye.

Other

  • GA due to causes other than dry AMD.
  • Any history or current evidence of exudative ("wet") AMD.

Who the study is looking for

  • Age ≥50 years at time of informed consent.
  • BCVA of 24 letters or better using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at screening.
  • Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (19)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Austin Clinical Research, LLCAustinUnited StatesUnknown status
Retina SpecialistsBaltimoreUnited StatesUnknown status
Ophthalmic Consultants of BostonBostonUnited StatesUnknown status
Star Vision ConsultantsBurlesonUnited StatesUnknown status
Rand Eye InstituteDeerfield BeachUnited StatesUnknown status
Advanced ResearchDeerfield BeachUnited StatesUnknown status
NJ RetinaEdisonUnited StatesUnknown status
Erie Retina Research LLCErieUnited StatesUnknown status
Verum Research, LLCEugeneUnited StatesUnknown status
National Ophthalmic Research InstituteFort MyersUnited StatesUnknown status
Texas Retina AssociatesFort WorthUnited StatesUnknown status
Long Island Vitreoretinal ConsultantsGreat NeckUnited StatesUnknown status
Tennessee Retina, PCNashvilleUnited StatesUnknown status
Phoenix Retina AssociatesPhoenixUnited StatesUnknown status
Retinal Consultants Medical GroupSacramentoUnited StatesUnknown status
Retina Consultants of TexasSan AntonioUnited StatesUnknown status
North Carolina Retina AssociatesWake ForestUnited StatesUnknown status
Bay Area Retina AssociatesWalnut CreekUnited StatesUnknown status
Center for Retina and Macular DiseaseWinter HavenUnited StatesUnknown status

Are you the coordinator? Confirm the details

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.